Research Roundup

innovation: candle, tungsten bulb, two modern light bulbs

Debbie Rigby takes a look at the latest in research news 

Lactobacillus reuteri reduces bone loss in older women with low bone mineral density

In this double‐blind, placebo‐controlled study, women from the population who were 75 to 80 years old and had low BMD were randomized to orally receive 1010 colony‐forming units of L. reuteri 6475 daily or placebo. The reduction in total vBMD in the distal tibia was nearly half as large in women taking the probiotic compared to placebo at 12 months.

Journal of Internal Medicine, first published 21 June 2018.


Ginkgo biloba extract for prevention of acute mountain sickness

Rapid ascent from low to high altitude (>2500 m above sea level) is often followed by headache, fatigue, shortness of breath, sleeplessness and anorexia, a symptom complex called acute mountain sickness. A systematic review and meta-analysis of randomised controlled trials suggests ginkgo biloba extract may tend towards acute mountain sickness prophylaxis, there are not enough data to show a statistically significant effect.

BMJ Open 2018.


Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus

Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding. In this trial of nearly 15,500 adults with diabetes and no evidence cardiovascular disease, aspirin use (100mg daily) reduced serious vascular events (MI, stroke, TIA, death) by 12%. It also caused major bleeding events, with nearly 30% increased incidence of gastrointestinal bleeding and other extracranial bleeding. The trial followed people for a mean duration of 7.4 years. The authors concluded that the absolute benefits were largely counterbalanced by the bleeding hazard.

New Engl J Med, first published August 26, 2018.


Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus

In this randomised placebo-controlled trial comparing omega-3 fatty acid 1g daily to placebo (olive oil) in people with diabetes but without evidence of atherosclerotic cardiovascular disease, there was no significant difference in the risk of serious vascular events (MI, stroke, TIA, vascular death) over a mean follow-up period of 7.4 years. There were no significant between-group differences in the rates of nonfatal serious adverse events.

New Engl J Med, first published August 26, 2018.



Previous New direction for Priceline
Next Multiple drugs implicated in death of doctor-shopping patient

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply